Background

- HER2-overexpressing breast cancer is a growing target for precision medicine.
- ZW25 is a novel HER2-targeting antibody.

Key Eligibility Criteria

- Patients must have HER2-positive cancer as determined by IHC 2+ and/or FISH-positive.
- Adequate bone marrow, liver, and kidney function.
- No prior HER2-directed therapy.
- No active brain metastases.

Study Design

- Phase 1: Dose-escalation study in HER2-positive malignancies.
- Patients are treated with single-agent ZW25.

Response in REOST 1.1 Evaluable Patients*

- Tumor response assessments per RECIST 1.1 (every 8 weeks).
- AE=adverse events
- BTC=biliary tract cancer; CRC=colorectal cancer; ECOG=Eastern Cooperative Oncology Group; FISH=fluorescence in situ hybridization.

Change in Target Lesions Across Cancer Types

- Majority of responders evaluated patients has disease in target lesions.

Conclusions

- ZW25 is a well-tolerated HER2-targeting antibody.
- HER2-positive patients achieve clinical benefit.
- Single-agent therapy with ZW25.

ZW25独特的亲和力和机理为HER2靶向治疗奠定了基础。本图展示了ZW25在不同癌种中的疗效，以及其在不同治疗阶段的疗效数据。

*Response rates are per RECIST 1.1 (any time interval).